Advancing Genetic Treatments Against Blindness
GenSight Biologics is an early clinical-stage biopharmaceutical company pioneering the development of gene therapy based solutions to preserve or restore vision in people with degenerative retinal and inherited ophthalmologic diseases
Based on recent results obtained by the teams of its scientific founders, the company develops innovative approaches to (i) prevent retinal degeneration in selected pathological conditions and (ii) to restore vision in patients suffering from very low vision or blindness.
Founded in 2012, the company is building on its close relationship with José Sahel, Botond Roska, Ernst Bamberg, Jean Bennett, Luk Vandenberghe and Connie Cepko, six of the world’s most renowned leading experts in this field and co-founders of GenSight Biologics.
Our strategic vision is to become the leader in gene therapy for ophthalmology diseases. We aim to develop, on the basis of our technology and know-how in the field of AAV vectors, optogenetics and genetic disorders, innovative therapeutic products that could avoid sight loss or restore vision in patients suffering from various forms of retinal degeneration.
Vision loss is the most feared consequence of disease apart from death. There are 15 million people in the Western world suffering from blindness or very limited vision, with few, if any treatments. Very limited vision and blindness are associated with very high costs (current estimates are more than €200 billion in the EU alone).
April 22-24, 2015: GenSight will present at the World Orphan Drug Congress in Washington DC, April 23-24, 2015. Jean-Philippe Combal, COO, will pitch on Friday April 24, at 10.40 am: "Pioneering the development of gene therapy based treatments for retinal degenerative diseases "
March 12, 2015: GenSight participated at the 5th Annual Advanced Therapies Summit, organized by the Alliance for Regenerative Medicine (ARM). Now member of the ARM, GenSight was part of Roundtable II: Gene Therapy in Europe & the U.S.
March 9-11, 2015: GenSight attended BioEurope Spring, Paris. GenSight presented in the category Partnerships in Regenerative Medicine and Advanced Therapies and participated at the roundtable: Next-generation treatments in ophthalmology: Can gene and cell-based therapies meet growing expectations for early clinical success?”.
February 21-26, 2015: GenSight attended NANOS, 41st Annual Meeting, in San Diego (CA) and presented: “Preliminary Safety and Tolerability Results Of A Recombinant Adeno-Associated Viral Vector Serotype 2 (rAAV2/2) Containing The Human Wild-Type Mitochondrial NADH Dehydrogenase 4 (ND4) Gene, In Patients With Leber Hereditary Optic Neuropathy Due To The G11778A Mitochondrial DNA Mutation”
January 12-16, 2015: GenSight presented at the 33rd Annual J.P. Morgan Healthcare Conference, San Francisco (CA), on Thursday, January 15, 2015 at 8:00 a.m. PT, room Elizabethan D.
January 7, 2015: GenSight Biologics, Pixium Vision and Fondation Voir et Entendre join forces and benefit from a total € 18.5 million funding for SIGHT AGAIN as part of the Investment for the Future
2015 Next events:
ARVO, May 3-7, 2015, Denver (Colorado)
ASGCT, May 13-16, 2015, New Orleans (Louisiana)
BIO, June 15-17, Philadelphia (PA)
2014 Major newss
December 3, 2014: Didier Pruneau, CSO of GenSight, featured at Gene Therapy (Dec. 3-4, 2014,Brussels) and gave a talk on "Translational development of GS010, an ocular mitochondrial gene therapy"
November 19-21, 2014 : GenSight presented at Therapeutic Area Partnership, in Boston (MA), as Top projects to watch in track #6 Advanced Therapies on Thursday 20, 2.15-2.30 pm
June 23-26, 2014: GenSight Biologics attended BIO, San Diego, CA, USA
May 21-22, 2014: GenSight Biologics presented in the the Next wave Companies list at BioEquity, Amsterdam, the Netherlands
May 4-9, 2014: GenSight Biologics attended ARVO annual meeting, Orlando, FL, USA and presented a poster:Safety, local tolerability and biodistribution of GS010 (AAV2/2-ND4), a gene therapy medicinal product in development for Leber Hereditary Optic Neuropathy (LHON), Physiology/Pharmacology, 342 Gene Therapy and Delivery, Poster Number: 3340 - B0280
March 10-12, 2014: GenSight Biologics presented at BioEurope Spring
February 28, 2014: GenSight Biologics expands its Series A round to the French seed fund for innovative biotherapies and rare diseases, Read the full press release (available only in French)
January 13-16, 2014: GenSight Biologics attended JP Morgan Healthcare Conference and Biotech Showcase, San Francisco, CA, USA
2013 Major news
October 2, 2013: GenSight, EuropaBio's Top 5 most innovative European biotech in 2013, Learn more
April 9, 2013: GenSight Biologics Raises €32m in a Series A Financing for Ophthalmic Gene Therapy. Learn more